Shanghai Lujiazui Finance & Trade Zone Development Co Ltd A

This evening, nearly 100 companies listed on the Shanghai Stock Exchange released a flurry of positive signals, spanning share buybacks and stake increases, improving business performance, proposed selections in centralized drug procurement, and interim dividend returns. On the buyback and stake increase front, two new buyback plans were added by Bethel Automotive Safety Systems and Shandong Hi-Speed, with a combined proposed buyback cap of 400 million yuan. Soochow Securities disclosed a controlling shareholder's stake increase plan, with a proposed increase amount not exceeding 200 million yuan, while another 76 companies simultaneously disclosed progress updates on buybacks and stake increases. At the operational level, results of the 12th round of national centralized drug procurement were gradually announced, with multiple Shanghai-listed pharmaceutical companies including Harbin Pharmaceutical Group, Zhejiang Huahai Pharmaceutical, China Resources Double-Crane Pharmaceutical, North China Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Aurisco Pharmaceutical, and Jianfeng Group declaring that their products have been proposed for selection. In terms of investor returns, four companies—WuXi AppTec, Zhejiang Jiuzhou Pharmaceutical, Kingfa Sci. & Tech., and Jasan Group—unveiled interim dividend plans on the same day. Among them, WuXi AppTec plans to distribute a cash dividend of 5.1 yuan per 10 shares, with the total interim dividend expected to exceed 1.5 billion yuan. Additionally, the controlling shareholder of Lujiazui voluntarily committed not to transfer or reduce its holdings in any way within the next 12 months, coinciding with the unlocking of restricted shares from the company's private placement.

Lujiazui has released its first-half 2026 report, with net profit attributable to shareholders reaching 1.108 billion yuan, a 35.91 percent increase compared to the same period last year. Total operating revenue was 8.098 billion yuan, up 22.75 percent year-on-year, marking three consecutive years of growth. Net cash inflow from operating activities stood at 5.407 billion yuan, a 14.20 percent rise year-on-year. The latest asset-liability ratio is 70.79 percent, gross margin is 57.92 percent, return on equity is 4.34 percent, and diluted earnings per share is 0.22 yuan.

Lujiazui released its 2026 half-year report, showing first-half net profit attributable to shareholders rose 35.9% year-on-year to 1.11 billion yuan. Operating revenue was 8.10 billion yuan, up 22.7% year-on-year. Recurring net profit attributable to shareholders was 1.11 billion yuan, up 34.4% year-on-year. Net operating cash flow was 5.407 billion yuan, up 14.2% year-on-year. Second-quarter operating revenue was 5.87 billion yuan, up 146.7% year-on-year, and net profit attributable to shareholders was 909 million yuan, up 392.1% year-on-year. As of the end of the second quarter, total assets stood at 171.844 billion yuan, up 2.7% from the end of the previous year.